nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—uterine cancer—muscle cancer	0.721	1	CtDrD
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—muscle cancer	0.136	0.802	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Etoposide—muscle cancer	0.0158	0.093	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vincristine—muscle cancer	0.007	0.0412	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Etoposide—muscle cancer	0.00641	0.0377	CbGbCtD
Medroxyprogesterone Acetate—AR—scrotum—muscle cancer	0.00617	0.224	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—muscle cancer	0.00437	0.0257	CbGbCtD
Medroxyprogesterone Acetate—SHBG—hindlimb—muscle cancer	0.00293	0.106	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Podofilox—Etoposide—muscle cancer	0.00156	0.592	CbGdCrCtD
Medroxyprogesterone Acetate—HSD3B2—head—muscle cancer	0.00133	0.0483	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—testis—muscle cancer	0.00129	0.0467	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Vinblastine—Vincristine—muscle cancer	0.00107	0.408	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—smooth muscle tissue—muscle cancer	0.000873	0.0316	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—cardiac atrium—muscle cancer	0.000752	0.0273	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—tendon—muscle cancer	0.000656	0.0238	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—bone marrow—muscle cancer	0.000635	0.023	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—vagina—muscle cancer	0.000608	0.0221	CbGeAlD
Medroxyprogesterone Acetate—PGR—smooth muscle tissue—muscle cancer	0.000591	0.0214	CbGeAlD
Medroxyprogesterone Acetate—ESR1—embryo—muscle cancer	0.000588	0.0213	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—testis—muscle cancer	0.000543	0.0197	CbGeAlD
Medroxyprogesterone Acetate—SHBG—bone marrow—muscle cancer	0.000477	0.0173	CbGeAlD
Medroxyprogesterone Acetate—AR—smooth muscle tissue—muscle cancer	0.000471	0.0171	CbGeAlD
Medroxyprogesterone Acetate—ESR1—smooth muscle tissue—muscle cancer	0.000462	0.0168	CbGeAlD
Medroxyprogesterone Acetate—SHBG—vagina—muscle cancer	0.000457	0.0166	CbGeAlD
Medroxyprogesterone Acetate—AR—renal system—muscle cancer	0.000453	0.0164	CbGeAlD
Medroxyprogesterone Acetate—ESR1—renal system—muscle cancer	0.000445	0.0161	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—embryo—muscle cancer	0.000434	0.0157	CbGeAlD
Medroxyprogesterone Acetate—PGR—vagina—muscle cancer	0.000412	0.0149	CbGeAlD
Medroxyprogesterone Acetate—SHBG—testis—muscle cancer	0.000408	0.0148	CbGeAlD
Medroxyprogesterone Acetate—AR—cardiac atrium—muscle cancer	0.000406	0.0147	CbGeAlD
Medroxyprogesterone Acetate—PGR—head—muscle cancer	0.000381	0.0138	CbGeAlD
Medroxyprogesterone Acetate—PGR—testis—muscle cancer	0.000368	0.0133	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—renal system—muscle cancer	0.000366	0.0133	CbGeAlD
Medroxyprogesterone Acetate—AR—tendon—muscle cancer	0.000354	0.0128	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—smooth muscle tissue—muscle cancer	0.000341	0.0124	CbGeAlD
Medroxyprogesterone Acetate—AR—vagina—muscle cancer	0.000328	0.0119	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—renal system—muscle cancer	0.000328	0.0119	CbGeAlD
Medroxyprogesterone Acetate—ESR1—vagina—muscle cancer	0.000322	0.0117	CbGeAlD
Medroxyprogesterone Acetate—AR—head—muscle cancer	0.000303	0.011	CbGeAlD
Medroxyprogesterone Acetate—ESR1—head—muscle cancer	0.000298	0.0108	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—cardiac atrium—muscle cancer	0.000294	0.0107	CbGeAlD
Medroxyprogesterone Acetate—AR—testis—muscle cancer	0.000293	0.0106	CbGeAlD
Medroxyprogesterone Acetate—ESR1—testis—muscle cancer	0.000288	0.0104	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—vagina—muscle cancer	0.000265	0.00963	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—tendon—muscle cancer	0.000256	0.00929	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—renal system—muscle cancer	0.000248	0.009	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—bone marrow—muscle cancer	0.000248	0.009	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—vagina—muscle cancer	0.000238	0.00862	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—testis—muscle cancer	0.000237	0.00859	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—head—muscle cancer	0.00022	0.00796	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—testis—muscle cancer	0.000212	0.00769	CbGeAlD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.000201	0.0563	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—muscle cancer	0.000156	0.0437	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.000144	0.0403	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.000129	0.0363	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Notch-mediated HES/HEY network—MYOD1—muscle cancer	0.000122	0.0343	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.000111	0.0311	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.000109	0.0306	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Vincristine—muscle cancer	9.62e-05	0.00128	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Vincristine—muscle cancer	9.61e-05	0.00128	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Etoposide—muscle cancer	9.59e-05	0.00128	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Vincristine—muscle cancer	9.53e-05	0.00127	CcSEcCtD
Medroxyprogesterone Acetate—Osteoarthritis—Doxorubicin—muscle cancer	9.53e-05	0.00127	CcSEcCtD
Medroxyprogesterone Acetate—Pain in extremity—Doxorubicin—muscle cancer	9.53e-05	0.00127	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Methotrexate—muscle cancer	9.51e-05	0.00127	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Etoposide—muscle cancer	9.42e-05	0.00125	CcSEcCtD
Medroxyprogesterone Acetate—Affect lability—Doxorubicin—muscle cancer	9.38e-05	0.00125	CcSEcCtD
Medroxyprogesterone Acetate—Migraine—Doxorubicin—muscle cancer	9.38e-05	0.00125	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	9.35e-05	0.00125	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Etoposide—muscle cancer	9.31e-05	0.00124	CcSEcCtD
Medroxyprogesterone Acetate—Face oedema—Doxorubicin—muscle cancer	9.2e-05	0.00123	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Dactinomycin—muscle cancer	9.19e-05	0.00122	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal discomfort—Methotrexate—muscle cancer	9.12e-05	0.00121	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Vincristine—muscle cancer	9.11e-05	0.00121	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Etoposide—muscle cancer	9.1e-05	0.00121	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Etoposide—muscle cancer	9.03e-05	0.0012	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Doxorubicin—muscle cancer	9.03e-05	0.0012	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Etoposide—muscle cancer	8.97e-05	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Doxorubicin—muscle cancer	8.96e-05	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Dactinomycin—muscle cancer	8.95e-05	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Blood creatinine increased—Doxorubicin—muscle cancer	8.93e-05	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Methotrexate—muscle cancer	8.89e-05	0.00118	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Etoposide—muscle cancer	8.84e-05	0.00118	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Methotrexate—muscle cancer	8.84e-05	0.00118	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Etoposide—muscle cancer	8.81e-05	0.00117	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Vincristine—muscle cancer	8.81e-05	0.00117	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Vincristine—muscle cancer	8.81e-05	0.00117	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Etoposide—muscle cancer	8.77e-05	0.00117	CcSEcCtD
Medroxyprogesterone Acetate—Dry skin—Doxorubicin—muscle cancer	8.73e-05	0.00116	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Etoposide—muscle cancer	8.73e-05	0.00116	CcSEcCtD
Medroxyprogesterone Acetate—Orthostatic hypotension—Doxorubicin—muscle cancer	8.7e-05	0.00116	CcSEcCtD
Medroxyprogesterone Acetate—Hypokalaemia—Doxorubicin—muscle cancer	8.67e-05	0.00115	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Doxorubicin—muscle cancer	8.61e-05	0.00115	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Etoposide—muscle cancer	8.61e-05	0.00115	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—muscle cancer	8.55e-05	0.024	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Dactinomycin—muscle cancer	8.54e-05	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Nasopharyngitis—Doxorubicin—muscle cancer	8.52e-05	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Methotrexate—muscle cancer	8.48e-05	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Methotrexate—muscle cancer	8.48e-05	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Methotrexate—muscle cancer	8.48e-05	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Depression—Methotrexate—muscle cancer	8.46e-05	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Etoposide—muscle cancer	8.44e-05	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Doxorubicin—muscle cancer	8.4e-05	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Muscular weakness—Doxorubicin—muscle cancer	8.4e-05	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Doxorubicin—muscle cancer	8.29e-05	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Methotrexate—muscle cancer	8.27e-05	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Doxorubicin—muscle cancer	8.24e-05	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Doxorubicin—muscle cancer	8.24e-05	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Doxorubicin—muscle cancer	8.24e-05	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Vincristine—muscle cancer	8.21e-05	0.00109	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Methotrexate—muscle cancer	8.13e-05	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Etoposide—muscle cancer	8.11e-05	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Etoposide—muscle cancer	8.05e-05	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Etoposide—muscle cancer	8.03e-05	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Methotrexate—muscle cancer	8.02e-05	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Methotrexate—muscle cancer	8e-05	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Vincristine—muscle cancer	8e-05	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Dactinomycin—muscle cancer	7.93e-05	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Bronchitis—Doxorubicin—muscle cancer	7.92e-05	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	7.92e-05	0.0222	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Dactinomycin—muscle cancer	7.87e-05	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Etoposide—muscle cancer	7.85e-05	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Etoposide—muscle cancer	7.8e-05	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Etoposide—muscle cancer	7.78e-05	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Etoposide—muscle cancer	7.72e-05	0.00103	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Doxorubicin—muscle cancer	7.7e-05	0.00103	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Doxorubicin—muscle cancer	7.65e-05	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Methotrexate—muscle cancer	7.65e-05	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Vincristine—muscle cancer	7.63e-05	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Methotrexate—muscle cancer	7.61e-05	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Methotrexate—muscle cancer	7.61e-05	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Doxorubicin—muscle cancer	7.61e-05	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Methotrexate—muscle cancer	7.56e-05	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Methotrexate—muscle cancer	7.52e-05	0.001	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Doxorubicin—muscle cancer	7.49e-05	0.000998	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Methotrexate—muscle cancer	7.46e-05	0.000994	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Doxorubicin—muscle cancer	7.45e-05	0.000992	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Etoposide—muscle cancer	7.44e-05	0.000991	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Doxorubicin—muscle cancer	7.43e-05	0.000989	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Dactinomycin—muscle cancer	7.41e-05	0.000987	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Etoposide—muscle cancer	7.38e-05	0.000983	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Vincristine—muscle cancer	7.37e-05	0.000982	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Doxorubicin—muscle cancer	7.34e-05	0.000978	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Doxorubicin—muscle cancer	7.34e-05	0.000978	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Doxorubicin—muscle cancer	7.34e-05	0.000978	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Methotrexate—muscle cancer	7.34e-05	0.000977	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	7.31e-05	0.0205	CbGpPWpGaD
Medroxyprogesterone Acetate—Erythema multiforme—Methotrexate—muscle cancer	7.2e-05	0.000959	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Doxorubicin—muscle cancer	7.2e-05	0.000959	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Etoposide—muscle cancer	7.17e-05	0.000955	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Doxorubicin—muscle cancer	7.16e-05	0.000953	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Doxorubicin—muscle cancer	7.16e-05	0.000953	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Etoposide—muscle cancer	7.14e-05	0.000951	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Etoposide—muscle cancer	7.14e-05	0.000951	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—muscle cancer	7.14e-05	0.000951	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Methotrexate—muscle cancer	7.11e-05	0.000947	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Methotrexate—muscle cancer	7.1e-05	0.000945	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Vincristine—muscle cancer	7.09e-05	0.000944	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Methotrexate—muscle cancer	7.06e-05	0.000941	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—muscle cancer	7.04e-05	0.000938	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Vincristine—muscle cancer	7.03e-05	0.000936	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Vincristine—muscle cancer	7.02e-05	0.000935	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Vincristine—muscle cancer	6.98e-05	0.00093	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—muscle cancer	6.94e-05	0.000925	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—muscle cancer	6.93e-05	0.000922	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Methotrexate—muscle cancer	6.91e-05	0.00092	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—muscle cancer	6.89e-05	0.000917	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Methotrexate—muscle cancer	6.88e-05	0.000916	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Methotrexate—muscle cancer	6.86e-05	0.000914	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Methotrexate—muscle cancer	6.83e-05	0.00091	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Methotrexate—muscle cancer	6.73e-05	0.000896	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—muscle cancer	6.71e-05	0.000894	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Methotrexate—muscle cancer	6.67e-05	0.000888	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Etoposide—muscle cancer	6.65e-05	0.000886	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Methotrexate—muscle cancer	6.63e-05	0.000883	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Methotrexate—muscle cancer	6.63e-05	0.000883	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—muscle cancer	6.63e-05	0.000882	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Vincristine—muscle cancer	6.62e-05	0.000882	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—muscle cancer	6.59e-05	0.000878	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—muscle cancer	6.59e-05	0.000878	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—muscle cancer	6.54e-05	0.000871	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—WT1—muscle cancer	6.52e-05	0.0183	CbGpPWpGaD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—muscle cancer	6.51e-05	0.000867	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—muscle cancer	6.49e-05	0.000865	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Methotrexate—muscle cancer	6.49e-05	0.000864	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Etoposide—muscle cancer	6.48e-05	0.000863	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—muscle cancer	6.48e-05	0.000863	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—muscle cancer	6.46e-05	0.000861	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Methotrexate—muscle cancer	6.41e-05	0.000854	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Etoposide—muscle cancer	6.39e-05	0.000851	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—muscle cancer	6.35e-05	0.000846	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—muscle cancer	6.23e-05	0.00083	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Etoposide—muscle cancer	6.18e-05	0.000823	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—muscle cancer	6.16e-05	0.00082	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Methotrexate—muscle cancer	6.15e-05	0.000819	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—muscle cancer	6.15e-05	0.000819	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Methotrexate—muscle cancer	6.12e-05	0.000816	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—muscle cancer	6.12e-05	0.000815	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	6.1e-05	0.0171	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	6.01e-05	0.0168	CbGpPWpGaD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—muscle cancer	5.98e-05	0.000796	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Methotrexate—muscle cancer	5.98e-05	0.000796	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Etoposide—muscle cancer	5.97e-05	0.000795	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—muscle cancer	5.95e-05	0.000793	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Methotrexate—muscle cancer	5.95e-05	0.000793	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—muscle cancer	5.94e-05	0.000791	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—muscle cancer	5.91e-05	0.000788	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—muscle cancer	5.82e-05	0.000776	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—muscle cancer	5.77e-05	0.000769	CcSEcCtD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—TP73—muscle cancer	5.75e-05	0.0161	CbGpPWpGaD
Medroxyprogesterone Acetate—Convulsion—Methotrexate—muscle cancer	5.74e-05	0.000765	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Etoposide—muscle cancer	5.74e-05	0.000765	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—muscle cancer	5.74e-05	0.000764	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—muscle cancer	5.74e-05	0.000764	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Etoposide—muscle cancer	5.69e-05	0.000758	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Etoposide—muscle cancer	5.69e-05	0.000758	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Etoposide—muscle cancer	5.66e-05	0.000753	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—muscle cancer	5.65e-05	0.000753	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Methotrexate—muscle cancer	5.64e-05	0.000751	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Methotrexate—muscle cancer	5.64e-05	0.000751	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Methotrexate—muscle cancer	5.64e-05	0.000751	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—muscle cancer	5.63e-05	0.00075	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Arachidonic acid metabolism—PTGS2—muscle cancer	5.63e-05	0.0158	CbGpPWpGaD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—muscle cancer	5.62e-05	0.000748	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	5.6e-05	0.000746	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of Androgen receptor activity—FOXO1—muscle cancer	5.58e-05	0.0157	CbGpPWpGaD
Medroxyprogesterone Acetate—Discomfort—Methotrexate—muscle cancer	5.57e-05	0.000742	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—muscle cancer	5.57e-05	0.000742	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—muscle cancer	5.55e-05	0.000739	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—muscle cancer	5.52e-05	0.000735	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Methotrexate—muscle cancer	5.45e-05	0.000726	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Methotrexate—muscle cancer	5.41e-05	0.00072	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	5.38e-05	0.0151	CbGpPWpGaD
Medroxyprogesterone Acetate—Infection—Methotrexate—muscle cancer	5.37e-05	0.000716	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Etoposide—muscle cancer	5.36e-05	0.000714	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—muscle cancer	5.32e-05	0.000709	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Methotrexate—muscle cancer	5.3e-05	0.000706	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—muscle cancer	5.3e-05	0.000706	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Methotrexate—muscle cancer	5.3e-05	0.000705	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—muscle cancer	5.27e-05	0.000702	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Methotrexate—muscle cancer	5.25e-05	0.0007	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Methotrexate—muscle cancer	5.23e-05	0.000696	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—muscle cancer	5.17e-05	0.000689	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—muscle cancer	5.16e-05	0.000687	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Methotrexate—muscle cancer	5.16e-05	0.000687	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—muscle cancer	5.15e-05	0.000685	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.13e-05	0.0144	CbGpPWpGaD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—muscle cancer	5.07e-05	0.000675	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Methotrexate—muscle cancer	5.05e-05	0.000673	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—muscle cancer	5.04e-05	0.000672	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—muscle cancer	4.97e-05	0.000662	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Methotrexate—muscle cancer	4.93e-05	0.000656	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Methotrexate—muscle cancer	4.89e-05	0.000651	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—muscle cancer	4.89e-05	0.000651	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—muscle cancer	4.89e-05	0.000651	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—muscle cancer	4.89e-05	0.000651	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—muscle cancer	4.87e-05	0.000648	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Methotrexate—muscle cancer	4.86e-05	0.000647	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	4.85e-05	0.000646	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—muscle cancer	4.83e-05	0.000643	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Methotrexate—muscle cancer	4.82e-05	0.000642	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Methotrexate—muscle cancer	4.81e-05	0.00064	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—muscle cancer	4.78e-05	0.000636	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Methotrexate—muscle cancer	4.76e-05	0.000634	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—muscle cancer	4.72e-05	0.000629	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Methotrexate—muscle cancer	4.7e-05	0.000626	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—muscle cancer	4.68e-05	0.000624	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—muscle cancer	4.68e-05	0.000624	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Methotrexate—muscle cancer	4.67e-05	0.000622	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Methotrexate—muscle cancer	4.66e-05	0.000621	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—muscle cancer	4.65e-05	0.00062	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—muscle cancer	4.61e-05	0.000614	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—muscle cancer	4.59e-05	0.000612	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—muscle cancer	4.59e-05	0.000611	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—muscle cancer	4.57e-05	0.000609	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—muscle cancer	4.55e-05	0.000606	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—muscle cancer	4.53e-05	0.000603	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—muscle cancer	4.46e-05	0.000595	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Methotrexate—muscle cancer	4.46e-05	0.000594	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Methotrexate—muscle cancer	4.42e-05	0.000589	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—muscle cancer	4.38e-05	0.000583	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—TP73—muscle cancer	4.36e-05	0.0122	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Methotrexate—muscle cancer	4.3e-05	0.000572	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Methotrexate—muscle cancer	4.28e-05	0.000569	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Methotrexate—muscle cancer	4.28e-05	0.000569	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—FOXO4—muscle cancer	4.27e-05	0.012	CbGpPWpGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—muscle cancer	4.27e-05	0.000568	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—muscle cancer	4.24e-05	0.000564	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Regulation of Androgen receptor activity—FOXO1—muscle cancer	4.23e-05	0.0119	CbGpPWpGaD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—muscle cancer	4.21e-05	0.00056	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—muscle cancer	4.18e-05	0.000556	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—muscle cancer	4.16e-05	0.000554	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	4.15e-05	0.0116	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—muscle cancer	4.12e-05	0.000549	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	4.08e-05	0.0115	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—muscle cancer	4.07e-05	0.000542	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—muscle cancer	4.04e-05	0.000538	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—FH—muscle cancer	4.04e-05	0.0113	CbGpPWpGaD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—muscle cancer	4.04e-05	0.000538	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—muscle cancer	4e-05	0.000533	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Methotrexate—muscle cancer	3.98e-05	0.000531	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	3.97e-05	0.0111	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Methotrexate—muscle cancer	3.88e-05	0.000517	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—muscle cancer	3.86e-05	0.000514	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—muscle cancer	3.83e-05	0.00051	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Methotrexate—muscle cancer	3.83e-05	0.00051	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—muscle cancer	3.72e-05	0.000495	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	3.71e-05	0.0104	CbGpPWpGaD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—muscle cancer	3.7e-05	0.000493	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—muscle cancer	3.7e-05	0.000493	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Methotrexate—muscle cancer	3.7e-05	0.000493	CcSEcCtD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—FOXO1—muscle cancer	3.69e-05	0.0103	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Methotrexate—muscle cancer	3.58e-05	0.000476	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—muscle cancer	3.47e-05	0.00972	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—muscle cancer	3.45e-05	0.00046	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Methotrexate—muscle cancer	3.44e-05	0.000458	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Methotrexate—muscle cancer	3.41e-05	0.000454	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Methotrexate—muscle cancer	3.41e-05	0.000454	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Methotrexate—muscle cancer	3.39e-05	0.000451	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—muscle cancer	3.36e-05	0.000447	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of Androgen receptor activity—MDM2—muscle cancer	3.35e-05	0.00939	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—muscle cancer	3.31e-05	0.000441	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—FOXO1—muscle cancer	3.26e-05	0.00913	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Methotrexate—muscle cancer	3.21e-05	0.000428	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—muscle cancer	3.2e-05	0.000427	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—CDKN2A—muscle cancer	3.2e-05	0.00898	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	3.18e-05	0.00892	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—FOXO1—muscle cancer	3.15e-05	0.00884	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—HMGA1—muscle cancer	3.12e-05	0.00874	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—muscle cancer	3.1e-05	0.000412	CcSEcCtD
Medroxyprogesterone Acetate—AR—Coregulation of Androgen receptor activity—CDKN2A—muscle cancer	3.09e-05	0.00865	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	3.06e-05	0.00859	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	3.02e-05	0.00846	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—muscle cancer	2.98e-05	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—muscle cancer	2.95e-05	0.000393	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—muscle cancer	2.95e-05	0.000393	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Doxorubicin—muscle cancer	2.93e-05	0.000391	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	2.85e-05	0.00801	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	2.79e-05	0.00781	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—muscle cancer	2.78e-05	0.00037	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	2.71e-05	0.0076	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of Androgen receptor activity—MDM2—muscle cancer	2.54e-05	0.00712	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.53e-05	0.0071	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—FOXO4—muscle cancer	2.51e-05	0.00703	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	2.48e-05	0.00697	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	2.41e-05	0.00677	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—KIT—muscle cancer	2.4e-05	0.00674	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—MED12—muscle cancer	2.38e-05	0.00667	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—MED12—muscle cancer	2.28e-05	0.00641	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—MDM2—muscle cancer	2.21e-05	0.0062	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	2.19e-05	0.00615	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—CDKN2A—muscle cancer	2.13e-05	0.00597	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	2.1e-05	0.00588	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—CDKN2A—muscle cancer	2.1e-05	0.00588	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	2.09e-05	0.00585	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—ENO2—muscle cancer	2.08e-05	0.00584	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KIDINS220—muscle cancer	2.07e-05	0.00581	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—FOXO1—muscle cancer	2.07e-05	0.00579	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	2.06e-05	0.00579	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—FH—muscle cancer	2e-05	0.0056	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—MDM2—muscle cancer	1.89e-05	0.00531	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	1.86e-05	0.00522	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—FOXO1—muscle cancer	1.85e-05	0.00519	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—MED12—muscle cancer	1.81e-05	0.00508	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	1.79e-05	0.00503	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—TP53—muscle cancer	1.75e-05	0.00491	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KIDINS220—muscle cancer	1.63e-05	0.00458	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.63e-05	0.00457	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	1.58e-05	0.00444	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	1.45e-05	0.00406	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—KIT—muscle cancer	1.41e-05	0.00395	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—MED12—muscle cancer	1.39e-05	0.00391	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—MED12—muscle cancer	1.37e-05	0.00385	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	1.29e-05	0.00361	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ENO2—muscle cancer	1.23e-05	0.00344	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.2e-05	0.00337	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TP53—muscle cancer	1.18e-05	0.00332	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TP53—muscle cancer	1.17e-05	0.00327	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.16e-05	0.00325	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MED12—muscle cancer	1.14e-05	0.00321	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—MED12—muscle cancer	1.13e-05	0.00316	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—MDM2—muscle cancer	1.12e-05	0.00313	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HMGA1—muscle cancer	1.12e-05	0.00313	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—MDM2—muscle cancer	1.11e-05	0.00311	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	1.1e-05	0.00309	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—VEGFA—muscle cancer	1.07e-05	0.00301	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ENO2—muscle cancer	1.03e-05	0.00288	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—muscle cancer	1.03e-05	0.00288	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—FOXO4—muscle cancer	1e-05	0.00281	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KIDINS220—muscle cancer	9.59e-06	0.00269	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	9.42e-06	0.00264	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	9.25e-06	0.00259	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	9.12e-06	0.00256	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	8.92e-06	0.0025	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MED12—muscle cancer	8.72e-06	0.00245	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	8.48e-06	0.00238	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—TP53—muscle cancer	8.31e-06	0.00233	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTCH1—muscle cancer	8.15e-06	0.00229	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—VEGFA—muscle cancer	8.13e-06	0.00228	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.04e-06	0.00226	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—FOXO1—muscle cancer	7.39e-06	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PTGS2—muscle cancer	7.25e-06	0.00203	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.12e-06	0.002	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	7.02e-06	0.00197	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FOXO4—muscle cancer	7.01e-06	0.00197	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.89e-06	0.00193	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CNR1—muscle cancer	6.88e-06	0.00193	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MED12—muscle cancer	6.72e-06	0.00188	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MED12—muscle cancer	6.61e-06	0.00186	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTCH1—muscle cancer	6.43e-06	0.0018	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—muscle cancer	6.41e-06	0.0018	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.8e-06	0.00163	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KIT—muscle cancer	5.63e-06	0.00158	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IGF2—muscle cancer	5.63e-06	0.00158	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—FH—muscle cancer	5.61e-06	0.00157	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FOXO4—muscle cancer	5.53e-06	0.00155	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CNR1—muscle cancer	5.43e-06	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.31e-06	0.00149	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FOXO1—muscle cancer	5.18e-06	0.00145	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—FH—muscle cancer	4.57e-06	0.00128	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IGF2—muscle cancer	4.44e-06	0.00124	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MDM2—muscle cancer	4.44e-06	0.00124	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTGS2—muscle cancer	4.28e-06	0.0012	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FOXO1—muscle cancer	4.08e-06	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KIT—muscle cancer	3.94e-06	0.00111	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTCH1—muscle cancer	3.77e-06	0.00106	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTGS2—muscle cancer	3.58e-06	0.001	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FOXO4—muscle cancer	3.25e-06	0.00091	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CNR1—muscle cancer	3.19e-06	0.000893	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—MED12—muscle cancer	3.17e-06	0.00089	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KIT—muscle cancer	3.11e-06	0.000873	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MDM2—muscle cancer	3.11e-06	0.000871	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—FH—muscle cancer	3.01e-06	0.000845	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ENO2—muscle cancer	2.89e-06	0.000811	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF2—muscle cancer	2.6e-06	0.00073	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—MED12—muscle cancer	2.58e-06	0.000724	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MDM2—muscle cancer	2.45e-06	0.000687	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FOXO1—muscle cancer	2.4e-06	0.000672	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—muscle cancer	2.36e-06	0.000662	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ENO2—muscle cancer	2.35e-06	0.00066	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.26e-06	0.000634	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—muscle cancer	1.86e-06	0.000522	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.84e-06	0.000516	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KIT—muscle cancer	1.83e-06	0.000512	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—muscle cancer	1.78e-06	0.0005	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MED12—muscle cancer	1.7e-06	0.000477	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ENO2—muscle cancer	1.55e-06	0.000435	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MDM2—muscle cancer	1.44e-06	0.000403	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—muscle cancer	1.41e-06	0.000394	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—muscle cancer	1.09e-06	0.000306	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS2—muscle cancer	1.01e-06	0.000282	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—muscle cancer	8.25e-07	0.000231	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS2—muscle cancer	8.2e-07	0.00023	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS2—muscle cancer	5.41e-07	0.000152	CbGpPWpGaD
